J. Schutte

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

R. Schmid, S. Hollerbach, D. Strumberg, 2012, British Journal of Cancer.

Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

E. Wardelmann, H. Joensuu, M. Schlemmer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Review of the clinical trials activity of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer.

J. Mulder, A. Santoro, H. Mouridsen, 1988, Seminars in surgical oncology.

Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

E. Wardelmann, H. Joensuu, M. Schlemmer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.

S. Johnston, G. Jerusalem, P. Conte, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.